According to Vertex Pharmaceuticals's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 10.4154. At the end of 2023 the company had a P/S ratio of 10.6.
Year | P/S ratio | Change |
---|---|---|
2023 | 10.6 | 27.99% |
2022 | 8.30 | 12.49% |
2021 | 7.38 | -25.49% |
2020 | 9.90 | -27.3% |
2019 | 13.6 | -1.82% |
2018 | 13.9 | -8.89% |
2017 | 15.2 | 41.87% |
2016 | 10.7 | -64.24% |
2015 | 30.0 | -39.33% |
2014 | 49.5 | 245.26% |
2013 | 14.3 | 140.39% |
2012 | 5.96 | 21.42% |
2011 | 4.91 | -90.13% |
2010 | 49.7 | -40.87% |
2009 | 84.1 | 243.25% |
2008 | 24.5 | 57.95% |
2007 | 15.5 | -28.9% |
2006 | 21.8 | 17.27% |
2005 | 18.6 | 123.8% |
2004 | 8.31 | -31.45% |
2003 | 12.1 | 61.36% |
2002 | 7.51 | -46.1% |
2001 | 13.9 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 3.79 | -63.65% | ๐บ๐ธ USA |
AbbVie ABBV | 5.20 | -50.04% | ๐บ๐ธ USA |
Gilead Sciences GILD | 3.01 | -71.12% | ๐บ๐ธ USA |
Merck MRK | 5.53 | -46.93% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | 2.02 | -80.59% | ๐บ๐ธ USA |
Enanta Pharmaceuticals
ENTA | 3.56 | -65.84% | ๐บ๐ธ USA |